Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201110147 Principal Investigator: Stockerl-Goldstein, Keith
Title: A Phase 2 Biomarker Study of Elotuzumab (Humanized anti-CS1 Monoclonal IgG1 Antibody) Monotherapy to Assess the Association between NK Cell Status and Efficacy in High Risk Smoldering Myeloma
Phase: II Disease Site: Multiple Myeloma
Participating Site(s):
 
Main Campus
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu
Description:
The purpose of this study is to find out if giving elotuzumab to patients with smoldering multiple myeloma leads to changes in certain cell types and protein levels in the blood. One of the secondary purposes of this study is to determine the effectiveness and safety of elotuzumab in patients with high risk smoldering multiple myeloma.
 
More Information:
CT.gov link
Internal Protocol Documents (requires Siteman administrative database password)